Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Acta Med Okayama ; 57(5): 217-25, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-14679399

RESUMEN

To improve the efficacy of interferon (IFN) treatment for chronic hepatitis C, we have proposed the twice-daily administration of IFN-beta as a promising induction therapy. In this study, we demonstrated differences between the clearance of circulating HCV-RNA and the induction of anti-viral actions during the first 2 weeks of treatment. Nine patients with a high viral load and genotype 1b were randomly assigned to 3 groups: group A received 3MU of IFN-beta twice a day at intervals of 5 and 19 h; group B received 3MU of IFN-beta twice a day at intervals of 10 and 14 h; group C received 6MU of IFN-alpha once a day with ribavirin. The expression of OAS2, PKR, and MxA in peripheral blood mononuclear cells (PBMCs) were quantified by real-time polymerase chain reaction method. The viral clearance showed a bi-phasic pattern, and those in the second phase of groups A and B were significantly steeper than that of group C. The peak level of OAS2 during the first phase was correlated with the first phase decay. The MxA expression tended to be higher in group A and B than in group C. The expression of these 3 proteins tended to decrease at day 6 in group C, but increase in groups A and B. These might make differences in the viral decay during the second phase


Asunto(s)
Antivirales/administración & dosificación , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/administración & dosificación , Interferón beta/administración & dosificación , ARN Viral/sangre , Ribavirina/administración & dosificación , 2',5'-Oligoadenilato Sintetasa/sangre , 2',5'-Oligoadenilato Sintetasa/genética , Adulto , Esquema de Medicación , Quimioterapia Combinada , Femenino , Proteínas de Unión al GTP/sangre , Proteínas de Unión al GTP/genética , Expresión Génica , Hepacivirus/genética , Hepatitis C Crónica/sangre , Hepatitis C Crónica/virología , Humanos , Cinética , Masculino , Persona de Mediana Edad , Monocitos/metabolismo , Proteínas de Resistencia a Mixovirus , Factores de Tiempo , eIF-2 Quinasa/sangre , eIF-2 Quinasa/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA